This study was performed to investigate the role of chronic pretreatment with angiotensin II type 1 receptor antagonists (ARB) and angiotensin converting enzyme inhibitors (ACE-I) in myocardial infarction (MI) and ischemic preconditioning (iPC). Little is known about molecular mechanisms of MI and iPC, especially about protein kinase C (PKC) isozyme levels induced by chronic pharmacologic pretreatment with ARB and ACE-I. To address one of the most important signal molecules in iPC, the PKC system was investigated in an ischemia/reperfusion model using isolated mouse hearts.
Viesturs Simanis, Andrea Krapp, Bastien Mangeat, Özge Uysal Özdemir
Charlotte Julie Caroline Gehin
Viesturs Simanis, Andrea Krapp, Bastien Mangeat, Özge Uysal Özdemir